Recent

% | $
Quotes you view appear here for quick access.

Novavax, Inc. Message Board

  • megapickh megapickh Sep 18, 2013 2:51 PM Flag

    (IPCI) MC $39 M // 8 Drugs awaiting FDA approval + 2x Blockbusters ready for P3 = 1000% Potential !!!

    FIRST FDA APPROVAL EXPECTED IN THIS 3Q 2013....

    This LOW FLOAT Monster awaiting 8 FDA approvals.IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including two Potential Blockbuster .CEO is the largest Shareholder with over 6 Million Shares .

    FOCALIN alone which is Partnered with Par Pharma will drive this Sleeping Giant into Profitability quickly after Market Launch because of the low Burn-rate of around $7 M a year !

    4-6 FDA APPROVALS COMING WITHIN NEXT 12 MONTHS = NEXT BILLION DOLLAR COMPANY HERE !

    Patience here will payoff big time ! GLTA

    Intellipharmaceutics (IPCI)

    Market Cap:$ 39 M
    Cash : $3 M
    Price: $2

    Shares Out: 21 Mil..(10 Mil Shares held by Insiders/Institutions)
    Low Float: 11 M

    8 Generic Drug Applications Filed with the FDA
    We currently have eight Abbreviated New Drug Applications awaiting FDA approval. These include generics of Focalin XR® Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.78 of branded and generic sales.

    Our lead product, a generic version of Focal in XR®, is partnered with Par Pharmaceuticals Inc., a top ten U.S.pharmaceutical company.As a result of a settlement with the innovator company, we expect to marketing of our generic versions ofFocalin XR® upon approval. We have a ten year profit-sharing agreement with Par for the sale of a generic version of Focal in XR® in the U.S.,which commences with the commercia/launch of the product by Par .
    -

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NVAX
2.36+0.10(+4.42%)1:50 PMEDT